Etanercept Immunex

Current Opinion in Investigational Drugs

Volumn 2, Issue 12, 2001, Pages 1725-1731

  Pugsley, Michael K ^a  

^a XOMA Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETANERCEPT; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CROHN DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ENDOMETRIOSIS; ERYTHEMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; LICENSING; MULTIPLE SCLEROSIS; NONHUMAN; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TOXICITY TESTING; TREATMENT INDICATION;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035689572     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Immunex and American home products revise research agreement
2. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group
3. Effects of therapy with soluble tumour necrosis factor receptor fusion protein on pulmonary cytokine expression and lung injury following haemorrhage and resuscitation
4. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists
5. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
6. Immunex and American Home Products' Pharmaceutical Division, Wyeth-Ayerst, to promote Enbrel in North America. Immunex research advances aimed at major pharmaceutical markets
7. Drug helps failing hearts by mopping up protein
8. Immunex's Enbrel safety data in juvenile rheumatoid arthritis clinical trial reported/efficacy trial of Enbrel in JRA continuing
9. Enbrel received FDA approval for treatment of rheumatoid arthritis. First in a new class of drugs is a breakthrough
10. Enbrel for juvenile rheumatoid arthritis indication filed with the Food and Drug Administration Immunex files supplemental application for Enbrel JRA indication following recent approval of Enbrel for treatment of adult rheumatoid arthritis
11. Pharmaceutical & biotechnology bulletin
12. Results of a multidose phase I trial with tumor necrosis factor receptor (p75) fusion protein (Etanercept) in patients with heart failure
13. Immunex and Wyeth-Ayerst Laboratories advanced Enbrel into phase II/III clinical trial for chronic heart failure
14. TNF Second International Meeting (Part II), A validated target with multiple therapeutic potential, Princeton, NJ, USA
15. Cardiovascular Pharmacotherapy - Eighth International Congress, Amsterdam, the Netherlands
16. Enbrel (etanercept) receives FDA approval for treatment of juvenile rheumatoid arthritis
17. Genentech and Immunex announce patent license agreement for immunoadhesin technology for Enbrel
18. Immunex/Genentech create fusion with Enbrel license, cancer deals
19. Interview: Targeted Genetics' delivery systems show promise
20. Immunex Novantrone MS use is likely to be second-line
21. Safety and efficacy of a soluble p75 tumour necrosis factor receptor (Enbrel, Etanercept) in patients with advanced heart failure
22. Enbrel (etanercept) follow-up study in chronic heart failure presented at American College of Cardiology meeting - Report on first patients to receive investigational treatment for CHF on sustained basis
23. Immunex reports first quarter 2000 results
24. Immunex plans Enbrel early RA consumer ad campaign for summer launch
25. Etanercept (TNF receptor fusion protein, Enbrel) is effective and well tolerated in active refractory Crohn's disease: Results of a single center pilot trial
26. Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Embrel, etanercept) in patients with advanced heart failure
27. Heart Failure - An Epidemic of the 21st Centry? 25th Institu Pasteur Euroconference, Paris, France
28. The pharmacokinetics of etanercept in healthy volunteers
29. Global healthcare bulletin
30. Revised EMEA public statement on etanercept (Enbrel) - Serious hematological reactions and demyelination disorders
31. Product information. ENBREL® (etanercept)
32. Drug development pipeline
33. Immunex decisions on continuing Enbrel CHF program awaits data analysis
34. Immunex: The product pipeline
35. The pharmacokinetics of etanercept in patients with heart failure
36. Enbrel (etanercept) becomes first product to be reviewed by FDA for treatment of psoriatric arthritis
37. Global Healthcare Bulletin
38. FDA assigns 'Priority Review' status to ENBREL (etanercept) sBLA for treatment of psoriatic arthritis
39. Colltech: CDP-870 - The original Ab-fab
40. The role of tumor necrosis factor in the pathophysiology of heart failure
41. TNF-α and heart failure. The difference between proof of principle and hypothesis testing
42. An overview of tumor necrosis factor α and the failing human heart
43. The role of anti-cytokine therapy in the failing heart
44. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure
45. Etanercept, a novel drug for the treatment of patients with severe active rheumatoid arthritis
46. Soluble TNF binding proteins modulate the negative inotropic properties of TNF-α in vitro
47. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats
48. Effects of etanercept on circulating tumor necrosis factor-α (TNF-α) in rats with ischemia-induced heart failure
49. Differential regulation of myocardial NF κ B following acute or chronic TNF-α exposure
50. Etanercept: A review of its use in rheumatoid arthritis
51. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure
52. Clinical trials update: CAPRICON, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001
53. Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis
54. Bad humours in heart failure: The role of tumor necrosis factor
55. Immunex reports third quarter 2001 results - Record sales of ENBREL (etanercept) at $198.1 million, net income up 26%, Fortune recognizes company as 'one of the top ten fastest growing' in the US; Immunex joins Standard & Poor's 500 Index
56. Immunex: News is good but stock run-up has been too